These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 9210678)

  • 1. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.
    Boyd MR; Gustafson KR; McMahon JB; Shoemaker RH; O'Keefe BR; Mori T; Gulakowski RJ; Wu L; Rivera MI; Laurencot CM; Currens MJ; Cardellina JH; Buckheit RW; Nara PL; Pannell LK; Sowder RC; Henderson LE
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1521-30. PubMed ID: 9210678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
    Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
    J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of cyanovirin-N (CV-N): inactivation of HIV-1 by sessile cyanovirin-N (sCV-N).
    Gandhi MJ; Boyd MR; Yi L; Yang GG; Vyas GN
    Dev Biol (Basel); 2000; 102():141-8. PubMed ID: 10794101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.
    Mori T; Boyd MR
    Antimicrob Agents Chemother; 2001 Mar; 45(3):664-72. PubMed ID: 11181340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development.
    Colleluori DM; Tien D; Kang F; Pagliei T; Kuss R; McCormick T; Watson K; McFadden K; Chaiken I; Buckheit RW; Romano JW
    Protein Expr Purif; 2005 Feb; 39(2):229-36. PubMed ID: 15642474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium.
    Mori T; Gustafson KR; Pannell LK; Shoemaker RH; Wu L; McMahon JB; Boyd MR
    Protein Expr Purif; 1998 Mar; 12(2):151-8. PubMed ID: 9518455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein.
    Mori T; Shoemaker RH; Gulakowski RJ; Krepps BL; McMahon JB; Gustafson KR; Pannell LK; Boyd MR
    Biochem Biophys Res Commun; 1997 Sep; 238(1):218-22. PubMed ID: 9299482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a cyanovirin-N-HIV-1 gp120 binding assay for high throughput screening of natural product extracts by time-resolved fluorescence.
    McMahon JB; Beutler JA; O'Keefe BR; Goodrum CB; Myers MA; Boyd MR
    J Biomol Screen; 2000 Jun; 5(3):169-76. PubMed ID: 10894760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120.
    Bewley CA; Otero-Quintero S
    J Am Chem Soc; 2001 May; 123(17):3892-902. PubMed ID: 11457139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
    Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
    J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells.
    Mori T; Shoemaker RH; McMahon JB; Gulakowski RJ; Gustafson KR; Boyd MR
    Biochem Biophys Res Commun; 1997 Oct; 239(3):884-8. PubMed ID: 9367864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyanovirin-N: a sugar-binding antiviral protein with a new twist.
    Botos I; Wlodawer A
    Cell Mol Life Sci; 2003 Feb; 60(2):277-87. PubMed ID: 12678493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein.
    Han Z; Simpson JT; Fivash MJ; Fisher R; Mori T
    Peptides; 2004 Apr; 25(4):551-61. PubMed ID: 15165709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides.
    Botos I; O'Keefe BR; Shenoy SR; Cartner LK; Ratner DM; Seeberger PH; Boyd MR; Wlodawer A
    J Biol Chem; 2002 Sep; 277(37):34336-42. PubMed ID: 12110688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High throughput screening for cyanovirin-N mimetics binding to HIV-1 gp41.
    Beutler JA; McMahon JB; Johnson TR; O'Keefe BR; Buzzell RA; Robbins D; Gardella R; Wilson J; Boyd MR
    J Biomol Screen; 2002 Apr; 7(2):105-10. PubMed ID: 12006108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity.
    Fromme R; Katiliene Z; Giomarelli B; Bogani F; Mc Mahon J; Mori T; Fromme P; Ghirlanda G
    Biochemistry; 2007 Aug; 46(32):9199-207. PubMed ID: 17636873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
    Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
    Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum.
    Gustafson KR; Sowder RC; Henderson LE; Cardellina JH; McMahon JB; Rajamani U; Pannell LK; Boyd MR
    Biochem Biophys Res Commun; 1997 Sep; 238(1):223-8. PubMed ID: 9299483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41.
    O'Keefe BR; Shenoy SR; Xie D; Zhang W; Muschik JM; Currens MJ; Chaiken I; Boyd MR
    Mol Pharmacol; 2000 Nov; 58(5):982-92. PubMed ID: 11040045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1.
    Giomarelli B; Provvedi R; Meacci F; Maggi T; Medaglini D; Pozzi G; Mori T; McMahon JB; Gardella R; Boyd MR
    AIDS; 2002 Jul; 16(10):1351-6. PubMed ID: 12131211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.